FOR IMMEDIATE RELEASE
Areterna LLC, a subsidiary of Synthgene Biotech, established for the purpose of providing raw materials and services tailored to mRNA and oligonucleotide therapeutics, has entered into a global distribution agreement with Medsol Corporation, a leading distributor of molecular biological and diagnostic products headquartered in Egypt. This partnership aims to enhance accessibility to high-quality, cost-effective raw materials and services for mRNA and oligo research and manufacturing in the Middle East and North Africa.
The collaboration between Areterna LLC and Medsol Corporation marks a significant step towards facilitating enhanced access to essential resources for mRNA and oligo research and manufacturing in the Middle East and North Africa markets. This strategic alliance is poised to benefit customers by providing them with enhanced access to vital materials necessary for the advancement of mRNA and oligo-related initiatives.
This agreement marks a pivotal moment in Areterna’s mission to democratize mRNA vaccines and therapeutics, highlighting the company’s dedication to delivering GMP-grade raw materials at competitive prices.
Simon Koerpert, Senior Director of Business Development EU at Areterna LLC, emphasized the importance of this partnership, stating,
“Through our collaboration with Medsol Corporation, we anticipate expanding our presence in the Middle East and North Africa markets, ultimately aiming to offer more affordable raw materials to support mRNA therapeutics development.”
Ahmed Ashour, Managing Director of Medsol Corporation, expressed enthusiasm for the partnership, emphasizing a shared belief in the vast potential of mRNA-based vaccines and therapeutics.
“Our collaboration with Areterna and Synthgene positions us to provide added value to our clients by granting access to premium raw materials at reduced costs. We eagerly anticipate the multitude of opportunities this partnership will unlock.”
About Areterna LLC:
Areterna LLC was founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd. to serve customers in the US and Europe. Synthgene provides materials and services to support mRNA and oligonucleotide manufacturing. Founded in 2018 by a group of passionate nucleic acid chemists, the goal of the company is to debottleneck the raw material supply and develop innovative solutions to support customers in the industry. The company has a robust quality system and ISO9001 certification to support cGMP manufacturing of mRNA raw materials that include NTPs, modified NTPs and cap analogs. For the GMP raw materials, Drug Master Files have been filed with FDA. In addition, Synthgene offers analytical development service and mRNA-related impurity standards and detection kits, LNP screening service, IVT process development and IVT kits for mRNA research. For solid-phase DNA and RNA synthesis, Synthgene offers high quality phosphonamidites to support cGMP oligo manufacturing. With over 200 scientists in R&D and AI-assisted discovery platform, Synthgene will continue to bring new products to the market.
About Medsol Corporation:
Medsol Corporation (www.medicalsolutionme.com) stands as a premier distributor of cutting-edge medical equipment and chemical reagents which has been operating since 2014 with HQ in Cairo, Egypt. Medsol Corporation transforms healthcare across the MENA region which strategically delivers innovative healthcare solutions with a strong tradition of excellence. Medsol Corporation is committed to revolutionizing the medical landscape, ensuring unparalleled quality and advancements in every market we serve.